Rapid expansion
Substantial market investment is leading to exponential growth in patients and procedures.
Rapid pace of innovation
Theranostics has a pipeline of potential new indications, therapies, and processes.
Rapid advancement of AI
With AI, personalized theranostics may be able to become the routine standard of care.
Rapid growth of new centers
The single sourcing of total molecular imaging needs is helping get clinical theranostics programs off the ground.
When other strategies have failed, theranostics has given hope that patient's lives might be extended so that they may have more time to spend with their loved ones
"Innovative theranostics therapies have the potential to be the next major pillar of cancer care, impacting the lives of hundreds of thousands of people and their families."
"This treatment remains a standard-of-care whilst also providing hope that next-generation theranostics will be able to cure patients with a variety of cancer types."
"Theranostics is the whole idea of working in nuclear medicine. Only the idea of using the same target for both diagnosis and therapy allows for effective treatment with minimal side effects. This is the future of medicine."
"With an increasing number of targets and radiolabels, the ability to treat what you see and see what you're treating is hitting the big time. And with the potential for personalization through radiation dosimetry, we can prospectively determine the dose we want to deliver and use our treatments more effectively."
"Recent advances in equipment technology, new dosimetry tools for personalized treatments, and development of new radiopharmaceuticals have placed nuclear medicine in the front row of cancer care."
Already chosen to treat patients with mCRPC, neuroendocrine tumors, thyroid and other cancers, researchers are exploring⁵ a wider range of cancers, such as brain, breast, pancreatic, and ovarian, that may be treatable with radioligand therapies in the next five to ten years.
Radionuclides like ¹⁷⁷Lu, ¹³¹I, and ⁹⁰Y have established themselves as effective cancer treatments.⁶ In the next few years, researchers are working to add several more radionuclides to the fight against cancers, including two alpha-emitting candidates, ²¹²Pb and ²²⁵Ac.⁵
Hundreds of clinical trials⁵ are well underway to explore the efficacy of radioligand therapy in battling many cancers. About a tenth of those trials are already in the late stages.
The sensitivity, resolution, and contrast capabilities of today's advanced PET and SPECT systems has produced remarkable images that can give confidence to theranostic practitioners.
¹⁷⁷Lu-PSMA therapy for prostate cancer
Patient qualification
Does the prostate cancer express PSMA, and if so, are the disease stage and the patient's clinical condition appropriate for treatment with ¹⁷⁷Lu-PSMA therapy? To find out, a radiopharmaceutical injection of ⁶⁸Ga-PSMA, or ¹⁸F-PSMA, can be given to the patient who is then imaged on a PET/CT or PET/MR scanner.
Personalized treatment
A course of up to 6 injections of the radiopharmaceutical, ¹⁷⁷Lu vipivotide tetraxetan, is administered to the patient. ¹⁷⁷Lu is a high-energy beta emitter which kills cancer cells. It also emits gamma rays, enabling it to be visualized on a NM camera (SPECT/CT).
Therapy response monitoring
After each of the therapy infusions, SPECT/CT imaging enables measuring quantitation of the tumor and the patient's response. SPECT/CT also allows personalized dosimetry calculations to help assess response and biodistribution of the treatments.
Follow-up monitoring and survivorship care
With the course of treatments complete, the patient undergoes regular check-ups and further imaging exams to monitor for recurrance or progression of the disease. Post-treatment survivorship care is provided to help improve the patient's quality of life.
Establishing your theranostics program as a Clinical Center of Excellence
Top-of-the-line discovery, diagnosis, and treatment monitoring solutions
6 Episodes
There is reason for hope because of theranostics
These are the stories of how Steve Fabiano, Doug Meijer, Ronald Foster and many like them have had their lease on life extended thanks to the exceptional care given by their BAMF Health team and the “miracle” that is theranostics.
Episode 1: New hope for patients
Episode 2: A vision for hope
These theranostics thought leaders share their perspectives on its beginnings and discuss why now it’s primed to change how we treat cancer, and soon other diseases. Personalized medicine is here, and this episode explores its anticipated growth.
Episode 3: Theranostics at BAMF Health
BAMF Health is pioneering efforts to deliver on their vision of personalized theranostics care. With an unwavering focus on patients and their caregivers, they aspire to provide quality care for those in need.
Episode 4: "New SPECT" for theranostics
Digital CZT SPECT/CT is a major enabler in theranostics. With the ability to identify the bio-distribution and perform dosimetry for therapies like ¹⁷⁷Lu, pioneering clinicians rely on SPECT/CT to monitor therapy.
Episode 5: Hope for many
Meet two patients, each thriving and enjoying life. They've been managing advanced stage prostate cancer for years. Their stories show how clinicians are treating and delivering precision medicine today.
Episode 6: Theranostics forward
This is just the beginning for theranostics. New targets, new disease states, and new tracers could usher in a surge of life-prolonging new treatment paradigms. Based on their personal experiences, these thought leaders help you prepare for this era of precision medicine.
Establishing a theranostics program: practical considerations
Dr. Medhat M. Osman, Chairman of Nuclear Medicine at St. Louis University speaks at SNMMI 2022
Neuro theranostics: next frontier for health span
Dr. Phillip H. Kuo, Senior Medical Director at University of Arizona speaks at SNMMI 2022
